12:00 AM
Jul 13, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Zebinix eslicarbazepine acetate: Additional Phase III data

Data from a 1-year extension of the Phase III BIA-2093-301 trial in 95 patients showed that eslicarbazepine as add-on therapy resulted in reduced mean seizure frequency by 61.8%. Also, 64.9% of patients achieved a >=50% reduction in seizure frequency and 8.5%...

Read the full 182 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >